Authors: Simon B. Drysdale, Rachael S. Barr, Christine S. Rollier, Christopher A. Green, Andrew J. Pollard, Charles J. Sande
Published: 2020-03-18
DOI: 10.1126/scitranslmed.aax2466
Source: Full article
About 38 candidate vaccines and monoclonal antibodies are in clinical development for treating respiratory syncytial virus in different populations.